Pfizer in a US$635 million Deal to Acquire Baxters Vaccines Portfolio
Published By : 05 Aug 2014 | Published By : QYRESEARCH
Pfizer Inc. has signed an agreement that will help the pharmaceuticals behemoth to acquire the marketed vaccines portfolio of Baxter International Inc. The deal, worth US$ 635 million, will also see Pfizer acquiring a part of the manufacturing unit in Orth, Austria where Baxter produces these vaccines.
Baxter has built an impressive portfolio of vaccines such as FSME-IMMUN/TicoVac and NeisVac-C. The latter helps immunize patients against meningitis, which is caused by MenC or group C meningococcal meningitis which leads to a deadly infection of the brain membrane. MenC is also one of the most common meningococcal serogroups in several pockets of the world. The NeisVac-C vaccine has proven highly effective for curbing this infection.
The other vaccine, FSME-IMMUN/TicoVac has proven effective in protecting against tick-borne encephalitis (TBE). This serious brain infection is transmitted via the bite of a TBE-virus-infected tick. The TBE virus has spiraled into a serious public health concern in countries in Asia and Europe, as well as other parts of the world. This vaccine enjoys approval in 30 countries, and has been in the market for three decades, with an estimated 120 million doses having been produced since 1976.
President of Pfizer Vaccines Susan Silbermann said that vaccines have a valuable role to play in public health initiatives the world over by mitigating the threat of widespread diseases that could also be fatal. With its latest acquisition, Pfizer will boost its life-saving vaccines portfolio. According to Pfizer, this transaction will not impact its 2014 financial guidance, which was issued in July 2014. Subject to various regulations and customary approvals, the transaction is expected to close by the end of 2014.